Terminated PHASE2 INTERVENTIONAL 1-arm NCT04720729

Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast Cancer (MONDRIAN)

Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study

Sponsor: Institut Curie

Conditions HER2-negative Metastatic Breast Cancer

Interventions Chemotherapy monitoring by circulating tumor DNA analysis

Updated 6 times since 2021 Last updated: Jun 17, 2025 Started: Apr 21, 2021 Primary completion: Apr 21, 2025 Completion: Apr 21, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

insufficient recruitment

Other terminated trials from Institut Curie

See all terminations from Institut Curie

A PHASE2 clinical study on HER2-negative Metastatic Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Institut Curie and has accumulated 6 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Jul 2025 — Present [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Sep 2024 — Jul 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Nov 2021 — Jul 2024 [monthly]

Recruiting PHASE2
May 2021 — Nov 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Feb 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institut Curie

Data source: Institut Curie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France